Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial
Rattachement africain : us, es, ca, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: There is limited evidence concerning the relationship between cardiometabolic characteristics and health-related quality of life (HRQoL), and potential effects of statin therapy among people with HIV (PWH). METHODS: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) enrolled PWH aged 40-75 years on antiretroviral therapy (ART) with low-to-moderate ASCVD risk. Coronary computed tomography angiography assessed coronary plaque among a subset of participants in the REPRIEVE Mechanistic Substudy at baseline and 24 months. The Short Form-36-Item Health Survey Version 2 was collected at baseline, and physical (PCS) and mental (MCS) component summary scores were determined. We explored the relationship of PCS and MCS with cardiometabolic characteristics, coronary atherosclerosis, and assessed change in score by treatment group (pitavastatin vs. placebo). RESULTS: Of 733 participants, median age was 51 years, 84% were male, 34% were Black non-Hispanic, and median years diagnosed with HIV was 15. At baseline, for participants randomized to pitavastatin vs. placebo the median PCS was 54.5 (Q1, Q3: 46.9, 57.7) vs. 54.1 (47.5, 58.0), and the median MCS was 52.9 (44.1, 57.6) vs. 52.8 (44.0, 57.9). In fully adjusted analyses, older age, Black non-Hispanic race/ethnicity, ART regimen class, elevated BMI, and cigarette smoking were associated with lower PCS. No clear trends were apparent with MCS. Between baseline and month 24, declines in PCS and MCS were minimal with no apparent difference by treatment group. CONCLUSIONS: Among this cohort of ART-treated PWH, baseline cardiometabolic risk factors were associated with worse self-reported physical HRQoL, with no apparent effect of statin therapy. TRIAL REGISTRATION: REPRIEVE; NCT02344290; https://clinicaltrials.gov/study/NCT02344290.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial
- Date Crossref
- 14/11/2025
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Massachusetts General Hospital Metabolism Unit pays non établi dans la noticeÉtablissement de santé
-
Cancer Research And Biostatistics pays non établi dans la noticeOrganisation à but non lucratif
-
University of Colorado Anschutz pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Research Institute pays non établi dans la noticeStructure de recherche
-
Duke Institute for Health Innovation pays non établi dans la noticeInstitution
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
Vall d'Hebron Institut de Recerca pays non établi dans la noticeStructure de recherche
-
Vall d'Hebron Hospital Universitari pays non établi dans la noticeÉtablissement de santé
-
Medical University of South Carolina Departments of Pediatrics and Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Maple Leaf Medical Clinic pays non établi dans la noticeÉtablissement de santé
-
Montgomery Botanical Center pays non établi dans la noticeInstitution
Harvard University, Metabolism Unit — Massachusetts General Hospital et Cancer Research And Biostatistics, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.